Earnings summaries and quarterly performance for IDEX CORP /DE/.
Executive leadership at IDEX CORP /DE/.
Eric Ashleman
Detailed
Chief Executive Officer and President
CEO
AM
Akhil Mahendra
Detailed
Interim Chief Financial Officer
LA
Lisa Anderson
Detailed
Senior Vice President, General Counsel and Corporate Secretary
MF
Melissa Flores
Detailed
Senior Vice President and Chief Human Resources Officer
RU
Roopa Unnikrishnan
Detailed
Senior Vice President, Chief Strategy and Innovation Officer
Board of directors at IDEX CORP /DE/.
AQ
Alejandro Quiroz
Detailed
Director
CC
Carl Christenson
Detailed
Director
KH
Katrina Helmkamp
Detailed
Non-Executive Chair of the Board
LG
Lakecia Gunter
Detailed
Director
MB
Mark Beck
Detailed
Director
MB
Mark Buthman
Detailed
Director
MG
Matthijs Glastra
Detailed
Director
PW
Paris Watts-Stanfield
Detailed
Director
SD
Stephanie Disher
Detailed
Director
Research analysts who have asked questions during IDEX CORP /DE/ earnings calls.
Deane Dray
RBC Capital Markets
9 questions for IEX
Also covers: AME, ATKR, CARR +20 more
VB
Vladimir Bystricky
Citigroup
9 questions for IEX
Also covers: ITT, ITW, MIR +1 more
BL
Brett Linzey
Mizuho Securities
8 questions for IEX
Also covers: AIRO, AIT, ALLE +15 more
JG
Joseph Giordano
TD Cowen
8 questions for IEX
Also covers: ABLZF, AME, APH +21 more
MH
Michael Halloran
Baird
8 questions for IEX
Also covers: AOS, CXT, DOV +19 more
NJ
Nathan Jones
Stifel, Nicolaus & Company, Incorporated
7 questions for IEX
Also covers: AOS, BMI, CR +20 more
AB
Andrew Buscaglia
BNP Paribas
6 questions for IEX
Also covers: AME, APH, CGNX +11 more
Bryan Blair
Oppenheimer
4 questions for IEX
Also covers: AOS, CSL, DCI +12 more
Robert Wertheimer
Melius Research
4 questions for IEX
Also covers: ALSN, AME, CAT +12 more
JS
Jeffrey Sprague
Vertical Research Partners
3 questions for IEX
Also covers: ALLE, AME, AYI +23 more
MS
Matt Summerville
D.A. Davidson & Co.
2 questions for IEX
Also covers: ALTG, AME, AOS +17 more
Nathan Jones
Stifel
2 questions for IEX
Also covers: AOS, BMI, CR +7 more
WL
Walt Liptak
Seaport Research
2 questions for IEX
Also covers: WOR
RJ
Rob Jamieson
TD Cowen
1 question for IEX
Also covers: KEYS, ST, ZBRA
RJ
Rob Jamison
Vertical Research Partners
1 question for IEX
Recent press releases and 8-K filings for IEX.
IDEX reports Q4 2025 results and issues 2026 guidance
IEX
Earnings
CFO Change
Guidance Update
- Sean Gillen joined as CFO in January, bringing over seven years of CFO experience at AAR Corp and a track record in operational efficiencies and disciplined capital allocation.
- In Q4 2025, organic revenue grew 1% and organic orders rose 16%, led by the Health & Science Technologies segment’s record $493 million in orders (+34% organically).
- Adjusted EBITDA margin expanded 40 bps year-over-year, with segment margin moves of +60 bps at HST, -20 bps at Fluid & Metering Technologies, and +50 bps at Fire, Safety & Specialty Products; adjusted EPS exceeded the guided range.
- Free cash flow was $190 million in Q4 and $617 million for FY 2025 (103% conversion), liquidity was $1.1 billion, and the company repurchased $73 million of shares in Q4 (total $250 million in 2025).
- For FY 2026, IDEX guides 1–2% organic growth, 26.5–27% adjusted EBITDA margin, an effective tax rate of 24%, and $8.15–8.35 in adjusted EPS; Q1 2026 outlook includes ~1% organic growth, 24.5% margin, and $1.73–1.78 EPS.
10 hours ago
IDEX reports Q4 2025 results
IEX
Earnings
Guidance Update
Share Buyback
- Organic revenue growth of 1% and adjusted EBITDA margin up 40 bps YoY in Q4; free cash flow of $617 m (103% of adj. NI) in FY 2025; $73 m in share repurchases in Q4
- HST segment: Q4 organic orders +34% to $493 m, organic sales +5%, and adj. EBITDA margin +60 bps YoY
- FMT segment: Q4 organic orders +4%, sales +1%, adj. EBITDA margin –20 bps; FSDP segment: orders flat, sales –5%, adj. EBITDA margin +50 bps
- 2026 guidance: organic growth 1–2%, adj. EBITDA margin 26.5–27%, adj. EPS $8.15–8.35; Q1 ’26 organic ~1%, adj. EBITDA margin ~24.5%, EPS $1.73–1.78
- Capital allocation: maintain investment-grade rating, continue organic investments and bolt-on M&A, return capital via dividends (30–35% of adj. NI) and share repurchases
11 hours ago
IDEX announces Q4 2025 results
IEX
Earnings
Guidance Update
Share Buyback
- IDEX delivered 1% organic revenue growth, 40 bps adjusted EBITDA margin expansion, and beat its EPS guidance in Q4 2025.
- The Health & Science Technologies segment saw 34% organic order growth, 5% revenue growth, and 60 bps margin expansion; Fluid & Metering Tech had 4% order growth, 1% sales growth, and a 20 bps margin decline; Fire, Safety & Dispensing orders were flat with 5% sales decline and 50 bps margin improvement.
- IDEX generated $190 M free cash flow in Q4 and $617 M for FY 2025 (103% cash conversion), ended with $1.1 B liquidity, and repurchased $73 M of shares in Q4 (total $250 M in 2025).
- For FY 2026, the company forecasts 1–2% organic growth, 26.5–27% EBITDA margin, and $8.15–8.35 EPS with a ~24% tax rate.
11 hours ago
IDEX reports Q4 and FY 2025 results
IEX
Earnings
Guidance Update
Share Buyback
- Record Q4 2025 net sales were $899 million, up 4% reported and 1% organically; reported diluted EPS was $1.71 (+6%) and adjusted diluted EPS was $2.10 (+3%).
- Full-year 2025 net sales reached $3.46 billion (+6% reported, +1% organic); adjusted diluted EPS was $7.95 (+1%) and free cash flow was $617 million (103% conversion).
- Q4 orders hit a record $979 million (+20% reported, +16% organic), driving full-year orders of $3.56 billion (+12% reported, +6% organic).
- IDEX repurchased $73 million of shares in Q4 and $248 million for the full year 2025.
- 2026 outlook calls for 1–2% organic sales growth, adjusted diluted EPS of $8.15–8.35, Q1 2026 organic sales up ~1% and adjusted EPS of $1.73–1.78.
14 hours ago
IDEX reports Q4 2025 results
IEX
Earnings
Guidance Update
Share Buyback
- IDEX delivered record Q4 sales of $899.1 million (+4% reported, +1% organic) and record orders of $979.2 million (+20% reported, +16% organic).
- Q4 reported diluted EPS rose to $1.71 (+6%), while adjusted diluted EPS reached $2.10 (+3%).
- FY 2025 net sales were $3.458 billion (+6% reported, +1% organic); adjusted diluted EPS was $7.95 (+1%); operating cash flow was $680.4 million (+2%) and free cash flow was $616.8 million (+2%), with a 103% conversion rate.
- The company repurchased $73 million of shares in Q4 and $248 million for the full year.
- 2026 outlook: organic sales up 1–2%, full-year adjusted diluted EPS of $8.15–8.35, and Q1 2026 adjusted diluted EPS of $1.73–1.78.
14 hours ago
IDEX reports Q4 2025 results
IEX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- IDEX reported Q4 revenues of $899 M, +1% organic, and adjusted EPS of $2.10, +3% y/y, with adj. EBITDA margin expanding 40 bps to 26.8%.
- Health & Science Technologies segment delivered record orders up 34% organic to $493 M and sales +5% organic to $408 M, with adj. EBITDA margin at 27.0% (+60 bps).
- Free cash flow conversion was 121% for Q4 and 101% for FY25, supporting balanced, returns-focused capital deployment.
- FY26 outlook guides 1–2% organic revenue growth, adjusted EBITDA margin of 26.5–27.0%, and adjusted EPS of $8.15–8.35.
14 hours ago
IDEX reports Q3 2025 results
IEX
Earnings
Share Buyback
M&A
- IDEX delivered 5% organic sales growth, 7% order growth, and 40 bps adjusted EBITDA margin expansion in Q3 2025, led by strong HST performance.
- The Health & Science Technology segment posted 10% sales growth, 5% orders growth, and 120 bps margin expansion on volume leverage, platform savings, and pricing actions.
- Fluid & Metering Technologies remained flattish, while Fire & Safety/Diversified Products faced headwinds from funding disruptions and subdued replenishment spend.
- Free cash flow reached $189 million (123% of adjusted net income), and IDEX repurchased $75 million of shares in the quarter, totaling $175 million year-to-date.
- Management continues to apply its 80/20 discipline and integrate recent acquisitions (e.g., Microlam, Nexsight, Subterra) to target advantaged markets such as water, data centers, and material science.
Oct 29, 2025, 1:00 PM
IDEX announces Q3 2025 results
IEX
Earnings
Guidance Update
Share Buyback
- IDEX delivered 7% organic orders growth and 5% organic revenue growth in Q3 2025, led by strong HST momentum with a record $390 million in orders.
- Health & Science Technology (HST) posted 5% organic orders growth, 10% sales growth, and 120 bps EBITDA margin expansion; Fluid & Metering Technologies (FMT) saw 8% orders growth, 4% sales growth, and 90 bps margin improvement.
- Fire & Safety/Diversified Products (FSDP) segment orders rose 7%, but sales declined 5%, resulting in a 200 bps EBITDA margin contraction.
- Free cash flow was $189 million with 123% conversion, liquidity of $1.1 billion, and $75 million of share repurchases in Q3 (**$175 million** YTD); buyback authorization increased to $1 billion.
- Full year guidance narrowed to $7.86–$7.91 EPS, with unchanged 1% organic growth and 26.5–27.5% adjusted EBITDA margin outlook.
Oct 29, 2025, 1:00 PM
IDEX reports Q3 2025 results
IEX
Earnings
Share Buyback
- IDEX delivered 5% organic revenue growth and 7% organic order growth in Q3, with adjusted EBITDA margin expanding 40 bps year-over-year.
- The Health and Science Technology (HST) segment achieved organic orders +5%, sales +10%, and adjusted EBITDA margin +120 bps.
- IDEX generated $189 M of free cash flow (123% conversion) and repurchased $75 M of shares in Q3 (YTD $175 M), maintaining $1.1 B of liquidity.
- Platform optimization and cost containment initiatives delivered $17 M in Q3 savings, on track for over $60 M of full-year savings.
Oct 29, 2025, 1:00 PM
IDEX reports Q3 2025 results
IEX
Earnings
Guidance Update
Share Buyback
- Record Q3 orders of $880 million (+13% reported, +7% organic) and sales of $879 million (+10% reported, +5% organic).
- GAAP diluted EPS of $1.70 (+8%) and adjusted diluted EPS of $2.03 (+7%).
- Narrowed full-year 2025 EPS guidance to $6.35–6.40 (GAAP) and $7.86–7.91 (adjusted).
- Returned capital with $75 million of share repurchases in Q3 (YTD $175 million) and raised buyback authorization to $1 billion.
Oct 29, 2025, 11:08 AM
Quarterly earnings call transcripts for IDEX CORP /DE/.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more